Menopausal hormone therapy and central nervous system tumor risk: Large UK prospective study and meta‐analysis
2014/10/21 by Victoria S. Benson, Oksana Kirichek, Valerie Beral +1 · 26 citations
Medicine · #Meningioma and schwannoma management #Pituitary Gland Disorders and Treatments #Brain Metastases and Treatment
paper · pdf · doi:10.1002/ijc.29274
Abstract
Female sex hormones are thought to affect women's risk of developing central nervous system (CNS) tumors. Some have reported an increased risk in users of menopausal hormone therapy (HT) but evidence is limited. In the UK General Practice Research Database we compared prospectively collected information on HT prescriptions in women aged 50-79 years with CNS tumors diagnosed in 1987-2011 with that in matched controls (four per case). Relative risks (RRs) in relation to prescribed HT were calculated overall and by CNS tumor subtype. Statistical tests are two-sided. For all CNS tumors (n = 3,500), glioma (n = 689), meningioma (n = 1,197), acoustic neuroma (n = 439), and pituitary tumors (n = 273) adjusted RRs for women prescribed HT versus not were, respectively, 1.21 (95% confidence intervals (CI) = 1.10-1.32, p < 0.0001), 1.14 (0.93-1.40, p = 0.2), 1.30 (1.11-1.51, p = 0.001), 1.37 (1.06-1.75, p = 0.01), and 1.35 (0.99-1.85, p = 0.06). There was no significant difference in risk by tumor subtype (p(heterogeneity) = 0.6). A meta-analysis was conducted, combining our results with those from other published studies with prospectively collected exposure information. The meta-analyses yielded significantly increased risks for all CNS tumors, glioma and meningioma in users of estrogen-only [1.35 (1.22-1.49), 1.23 (1.06-1.42) and 1.31 (1.20-1.43), respectively] but not estrogen-progestin HT [1.09 (0.99-1.19), 0.92 (0.78-1.08) and 1.05 (0.95-1.16), respectively]; these differences were statistically significant (p < 0.005 for each tumor type). There was no significant difference between glioma and meningioma risk in users of estrogen-only HT. The totality of the available evidence suggests an increased risk of all CNS tumors (and of glioma and meningioma separately) in users of estrogen-only HT. Absolute excess risk (2 per 10,000 users over 5 years) is small.
Citations
Cited by
- Estrogen and Progesterone Therapy and Meningiomas
- Menopausal hormone therapy use and risk of primary liver cancer in the clinical practice research datalink. [europepmc]
- Molecular Genetics of Intracranial Meningiomas with Emphasis on Canonical Wnt Signalling. [europepmc]
- Diabetes, use of metformin, and the risk of meningioma. [europepmc]
- Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. [europepmc]
- Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the Multiethnic Cohort. [europepmc]
- Hormone Replacement Therapy in Cancer Survivors - Review of the Literature. [europepmc]
- Factors Associated With Meningioma Detected in a Population-Based Sample. [europepmc]
- Sex Hormones and Optic Nerve Disorders: A Review. [europepmc]
- Genetic and molecular epidemiology of adult diffuse glioma. [europepmc]
- Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study. [europepmc]
- Soy Isoflavone Improved Female Sexual Dysfunction of Mice Via Endothelial Nitric Oxide Synthase Pathway. [europepmc]
- A prospective study of the natural history of incidental meningioma-Hold your horses! [europepmc]
- Associations of Urinary Phytoestrogen Concentrations with Sleep Disorders and Sleep Duration among Adults. [europepmc]
- Sex-specific aspects of epidemiology, molecular genetics and outcome: primary brain tumours. [europepmc]
- Meningiomas in Premenopausal Women: Role of the Hormone Related Conditions. [europepmc]
- Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions. [europepmc]
- The risk of developing a meningioma during and after pregnancy. [europepmc]
- A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas. [europepmc]
- Spinal meningiomas, from biology to management - A literature review. [europepmc]
- Long-term air pollution exposure and malignant intracranial tumours of the central nervous system: a pooled analysis of six European cohorts. [europepmc]
- The causal relationship between genetically determined telomere length and meningiomas risk. [europepmc]
- Menopausal hormone therapy and central nervous system tumors: Danish nested case-control study. [europepmc]
- Use of progestogens and the risk of intracranial meningioma: national case-control study. [europepmc]
- Bridging the gap: exploring the causal relationship between metformin and tumors. [europepmc]
- Recommendations on the management of meningioma and sex hormone therapy: The results of a collaborative effort between neurosurgical, endocrine and gynecological societies. [europepmc]
Related